JPRN-jRCT1031220271尚未招募2 期
Effects of combination therapy of insulin degludec and oral hypoglycemic agents on hyperglycemia in patients with type 2 diabetes: a randomized controlled study
Kazuki Orime0 个研究点目标入组 100 人开始时间: 2022年8月15日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 尚未招募
- 发起方
- 入组人数
- 100
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 < 80age old（—）
- 性别
- All
入选标准
- •(1) Patients with type 2 diabetes aged 20 years or older and less than 80 years old at the time of registration
- •(2) Gender is irrelevant.
- •(3) Patients with 9.0% =< HbA1c =< 12.0% at the time of medical checkup.
- •(4) Patients with blood glucose level of 170 mg/dl or more at any time at the time of examination
- •(5) Patients must not have received treatment with insulin, GLP-1 receptor agonists, or SGLT2 inhibitors within 8 weeks prior to enrollment.
- •(6) Patients who provide written consent to participate in this study
- •(7) Patients taking up to 3 oral hypoglycemic agents
- •(8) For patients taking oral SU medications, the dose of SU medication should not exceed 2 mg/day for glimepiride, 1.25 mg/day for glibenclamide, and 40 mg/day for gliclazide.
排除标准
- •(1) Patients with type 1 diabetes or secondary diabetes
- •(2) Patients with severe renal dysfunction (eGFR <30 ml/min/1.73m2)
- •(3) Patients with severe hepatic dysfunction (AST, ALT > 3 times the upper limit of normal)
- •(4) Patients on steroids (oral or injectable steroids)
- •(5) Patients taking atypical antipsychotics
- •(6) Patients on immune checkpoint inhibitors (anti-PD-1, anti-PD-L1, anti-CTLA-4 antibodies)
- •(7) Patients with active carcinoma (however, those who have not received any treatment for it and have no evidence of recurrence, and those who can be judged not to have recurred during this study period will be included)
- •(8) Patients with severe infections (when symptoms of infection such as fever and diarrhea do not improve after 3 days of antibiotic treatment)
- •(9) Patients with severe trauma (Injury Severity Score (ISS) anatomical severity > 15)
- •(10) Patients with contraindications or allergies to the study drug
- •(11) Patients who are pregnant, may become pregnant, or wish to become pregnant during the study period
- •(12) Patients who are judged to have difficulty maintaining compliance during the study period
- •(13) Patients in diabetic coma
研究者
相似试验
进行中（未招募）
不适用
The effect of insulin degludec in combination with liraglutide and metformin in subjects with type 2 diabetes qualifying for treatment intensificatioMedDRA version: 14.1Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersDiabetes Mellitus, Type 2EUCTR2011-004665-32-GBovo Nordisk A/S320
进行中（未招募）
不适用
The effect of insulin degludec in combination with liraglutide and metformin in subjects with type 2 diabetes qualifying for treatment intensification.Diabetes Mellitus Type 2MedDRA version: 15.0Level: LLTClassification code 10045242Term: Type II diabetes mellitusSystem Organ Class: 10027433 - Metabolism and nutrition disordersEUCTR2011-004665-32-ITOVO NORDISK320
进行中（未招募）
不适用
The effect of insulin degludec in combination with liraglutide and metformin in subjects with type 2 diabetes qualifying for treatment intensificatioDiabetes Mellitus, Type 2EUCTR2011-004665-32-DEovo Nordisk A/S320
招募中
3 期
Effect of synbiotic in treatment of diabetesIRCT20220313054269N1Islamic Azad University, Science and Research Branch76
进行中（未招募）
不适用
The efficacy of insulin degludec/liraglutide in controlling glycaemia in adults with type 2 diabetes inadequately controlled on GLP-1 receptor agonist and metformin therapyDiabetes Mellitus, Type 2EUCTR2012-000209-63-SKovo Nordisk A/S429